$18.14
0.32% today
Nasdaq, Nov 03, 08:14 pm CET

Innoviva Stock price

$18.20
-0.05 0.27% 1M
-0.49 2.62% 6M
+0.85 4.90% YTD
-1.36 6.95% 1Y
+4.64 34.22% 3Y
+7.95 77.56% 5Y
+9.30 104.49% 10Y
+0.74 4.26% 20Y
Nasdaq, Closing price Fri, Oct 31 2025
+0.25 1.39%

Key metrics

Basic
Market capitalization
$1.1b
Enterprise Value
$1.1b
Net debt
positive
Cash
$497.7m
Shares outstanding
63.0m
Valuation (TTM | estimate)
P/E
40.4 | 15.3
P/S
3.1 | 3.0
EV/Sales
3.0 | 2.8
EV/FCF
5.5
P/B
1.6
Dividends
DPS
$0.00
Yield 1Y | 5Y
0.0% | 0.0%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
0.0% | 0.0%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$370.2m | $387.3m
EBITDA
$216.5m | $160.0m
EBIT
$176.6m | $173.7m
Net Income
$38.7m | $75.0m
Free Cash Flow
$200.6m
Growth (TTM | estimate)
Revenue
12.0% | 8.0%
EBITDA
33.8% | -17.0%
EBIT
29.9% | 4.1%
Net Income
-73.4% | 220.6%
Free Cash Flow
27.4%
Margin (TTM | estimate)
Gross
86.6%
EBITDA
58.5% | 41.3%
EBIT
47.7%
Net
10.4% | 19.4%
Free Cash Flow
54.2%
Financial Health
Equity Ratio
53.1%
Return on Equity
3.4%
ROCE
16.2%
ROIC
12.9%
Debt/Equity
0.6
More
EPS
$0.5
FCF per Share
$3.2
Short interest
14.2%
Employees
127
Rev per Employee
$2.8m
Show more

Is Innoviva a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.

Innoviva Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Innoviva forecast:

9x Buy
82%
1x Hold
9%
1x Sell
9%

Analyst Opinions

11 Analysts have issued a Innoviva forecast:

Buy
82%
Hold
9%
Sell
9%

Financial data from Innoviva

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
370 370
12% 12%
100%
- Direct Costs 50 50
16% 16%
13%
321 321
11% 11%
87%
- Selling and Administrative Expenses 111 111
1% 1%
30%
- Research and Development Expense 20 20
53% 53%
5%
217 217
34% 34%
58%
- Depreciation and Amortization 40 40
54% 54%
11%
EBIT (Operating Income) EBIT 177 177
30% 30%
48%
Net Profit 39 39
73% 73%
10%

In millions USD.

Don't miss a Thing! We will send you all news about Innoviva directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Innoviva Stock News

Neutral
PRNewsWire
13 days ago
d'Esparbes to lead Antheia's financial strategy as the company continues its global expansionand commercialization MENLO PARK, Calif. , Oct. 21, 2025 /PRNewswire/ --  Antheia , the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, today announced the appointment of Eric d'Esparbes as Chief Financial Officer.
Neutral
Business Wire
14 days ago
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ: INVA), will share new data on zoliflodacin during the Infectious Disease Society of America's IDWeek 2025 annual meeting in Atlanta, GA, October 19-22, 2025. Zoliflodacin is a first-in-class oral antibiotic being developed for the treatment of uncomplicated gonorrhea. Three sets of data wil...
Neutral
Business Wire
27 days ago
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced that it will deliver data from six presentations at IDWeek 2025, including clinical data, pharmacokinetic-pharmacodynamic (PK-PD) analyses, and microbiologic surveillance from its growing portfolio of antibiotics and critical care medicines. IDWeek will be held in Atl...
More Innoviva News

Company Profile

Innoviva, Inc. is engaged in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

Head office United States
CEO Mr. Raifeld
Employees 127
Founded 1996
Website www.inva.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today